VARLOTA

This brand name is authorized in Estonia, Lithuania, Malta, Poland

Active ingredients

The drug VARLOTA contains one active pharmaceutical ingredient (API):

1 Erlotinib UNII DA87705X9K - ERLOTINIB HYDROCHLORIDE

Erlotinib is an epidermal growth factor receptor/human epidermal growth factor receptor type 1 (EGFR also known as HER1) tyrosine kinase inhibitor. Erlotinib potently inhibits the intracellular phosphorylation of EGFR. EGFR is expressed on the cell surface of normal cells and cancer cells. Due to the blocking of downstream-signaling, the proliferation of cells is stopped, and cell death is induced through the intrinsic apoptotic pathway. Read about Erlotinib

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EB02	Erlotinib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
Discover more medicines within L01EB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1698969, 1698970, 1698981
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1078244, 1078245, 1078246
Country: MT	Medicines Authority	Identifier(s): AA729/27601, AA729/27602
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100356685, 100356691, 100356700, 100356716